(CIDRAP News) The National Institute of Allergy and Infectious Diseases (NIAID) has released a 68-page report on its plan for expanding research on "Category A" bioterrorism agents: anthrax, smallpox, plague, tularemia, viral hemorrhagic fevers, and botulism.
(CIDRAP News) – The US Department of Health and Human Services yesterday announced $350 million in grants for eight regional centers to lead and coordinate research on defenses against bioterrorism and emerging infectious diseases.
(CIDRAP News) Federal health officials yesterday released a 37-page report that they say demonstrates "tremendous progress" in developing countermeasures for bioterrorism through federally funded research since early 2002.
Editor's note: A correction was made in this story Nov 9 to note that the existing licensed anthrax vaccine contains the natural rather than recombinant form of anthrax protective antigen.
(CIDRAP News) Federal health officials today announced the award of an $877 million contract for 75 million doses of a new anthrax vaccine to protect the public and improve on the existing vaccine used by the military.
Editor's note: This story was revised shortly after publication to reflect corrections issued by the National Institute of Allergy and Infectious Diseases on May 10. The corrections pertain to the total monetary amount of the grants and to the project descriptions for XOMA (US) LLC and DVC Dynport LLC.
Aug 11, 2004 (CIDRAP News) Government officials and scientists yesterday recognized the formal opening of construction on a laboratory that will house research on the most dangerous emerging infectious diseases and potential bioterrorism agents.
(CIDRAP News) – Combining vaccination with 14 days of antibiotic therapy after exposure to airborne anthrax may be an alternative to the current recommendation of 60 days of antibiotics alone, according to an animal study reported in the Proceedings of the National Academy of Sciences.
(CIDRAP News) – The US government recently awarded contracts totaling about $34 million to two companies for development of drugs to treat pneumonic plague, tularemia, and anthrax, three of the diseases terrorists are deemed most likely to try to exploit.
(CIDRAP News) US Navy and Air Force officials recently reported a suspension of work in their biodefense laboratories to allow a thorough review of safety procedures, following the Army's announcement in early August that it would review security measures at the lab that housed the work of the late Bruce E. Ivins, whom federal officials believe played a role in the 2001 anthrax attacks.